Table 4 Plaque phenotypic... | American Society of Hematology

Table 4

Plaque phenotypic characteristics after anti-CD25 treatment

	Cd40l^+/+ Apoe^−/−	Cd40l^+/+Apoe^−/− + anti-CD25	Cd40l^−/− Apoe^−/−	Cd40l^+/+Apoe^−/− + anti-CD25
% CD3	4.5 ± 0.8	4.9 ± 0.4	2.7 ± 0.7*	2.9 ± 0.4
% CD45	9.7 ± 1.7	8.3 ± 1.7	6.8 ± 1.2	7.4 ± 1.6
% Mac3	56.4 ± 8.2	60.6 ± 4.9	64.2 ± 4.8	58.7 ± 3.2
MAC-3 Abs	144.2 ± 23.2	161.4 ± 19.6	151.6 ± 13.6	163.7 ± 27.2
Caspase-3⁺	2.0 ± 0.4	1.7 ± 0.3	2.0 ± 0.2	2.0 ± 0.2
% α-SMA	24.7 ± 5.7	14.5 ± 2.2	24.6 ± 4.6	16.1 ± 2.7
% SR	64.2 ± 5.7	57.1 ± 2.2	55.1 ± 2.2	66.6 ± 3.6
% LC	17.4 ± 3.5	18.7 ± 2.4	12.9 ± 3.1	18.1 ± 3.7

	Cd40l^+/+ Apoe^−/−	Cd40l^+/+Apoe^−/− + anti-CD25	Cd40l^−/− Apoe^−/−	Cd40l^+/+Apoe^−/− + anti-CD25
% CD3	4.5 ± 0.8	4.9 ± 0.4	2.7 ± 0.7*	2.9 ± 0.4
% CD45	9.7 ± 1.7	8.3 ± 1.7	6.8 ± 1.2	7.4 ± 1.6
% Mac3	56.4 ± 8.2	60.6 ± 4.9	64.2 ± 4.8	58.7 ± 3.2
MAC-3 Abs	144.2 ± 23.2	161.4 ± 19.6	151.6 ± 13.6	163.7 ± 27.2
Caspase-3⁺	2.0 ± 0.4	1.7 ± 0.3	2.0 ± 0.2	2.0 ± 0.2
% α-SMA	24.7 ± 5.7	14.5 ± 2.2	24.6 ± 4.6	16.1 ± 2.7
% SR	64.2 ± 5.7	57.1 ± 2.2	55.1 ± 2.2	66.6 ± 3.6
% LC	17.4 ± 3.5	18.7 ± 2.4	12.9 ± 3.1	18.1 ± 3.7

P < .05 vs Cd40l^+/+Apoe^−/−.